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Abstract: Infection of mice with Coxsackievirus B3 (CVB3) triggers inflammation of the heart and this
mouse model is commonly used to investigate underlying mechanisms and therapeutic aspects for
viral myocarditis. Virus-triggered cytotoxicity and the activity of infiltrating immune cells contribute
to cardiac tissue injury. In addition to cardiac manifestation, CVB3 causes cell death and inflammation
in the pancreas. The resulting pancreatitis represents a severe burden and under such experimental
conditions, analgesics may be supportive to improve the animals’ well-being. Notably, several known
mechanisms exist by which analgesics can interfere with the immune system and thereby compromise
the feasibility of the model. We set up a study aiming to improve animal welfare while ensuring
model integrity and investigated how tramadol, an opioid, affects virus-induced pathogenicity and
immune response in the heart. Tramadol was administered seven days prior to a CVB3 infection in
C57BL/6 mice and treatment was continued until the day of analysis. Tramadol had no effect on the
virus titer or viral pathogenicity in the heart tissue and the inflammatory response, a hallmark of
myocardial injury, was maintained. Our results show that tramadol exerts no disruptive effects on
the CVB3 myocarditis mouse model and, therefore, the demonstrated protocol should be considered
as a general analgesic strategy for CVB3 infection.
Keywords: infection; myocarditis; pancreatitis; refinement; analgesia
1. Introduction
Myocarditis is an inflammatory disease of the heart, frequently induced by virus infec-
tions [1]. In order to investigate pathogenic mechanisms of virus-induced myocarditis and
subsequent inflammatory processes with alterations in the extracellular matrix of the heart,
most researchers rely on the Coxsackievirus B3 (CVB3) myocarditis model in mice [2–5].
This model mimics the general aspects of viral myocarditis in humans and shows primary
virus replication in the intestinal organs (enterovirus [6] and adenovirus [7]), the lung
(influenza virus, some indication also for SARS-CoV2 [8–10]) or skin (rubella virus [11]),
with viruses spreading via the blood stream (viremia) and subsequent infections of the
heart. It was established about 60 years ago by intraperitoneal (i.p.) infection of mice with
CVB3 [12]. Induced by viral infection of the cardiomyocytes, the pathogenesis of viral
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myocarditis is driven by virus-caused cell destruction and the infection-triggered activation
of the immune system, whereby inflammatory processes are of particular importance for
this model [2]. The sensing of viral replication intermediates by their cognate receptors
triggers pro-inflammatory molecules and stimulates the infiltration of immune cells. Natu-
ral killer (NK) cells and monocytes/macrophages represent classic infiltrating cells and,
to a minor extent, B-lymphocytes and T-lymphocytes also invade. Undisputedly, the im-
mune response is required for virus control, but there is also consensus that inflammatory
processes drive cardiac damage and fibrotic remodeling [4,13].
In mice, the pancreas is the most vulnerable organ for CVB3 infection and mice
develop pancreatitis in the first couple of days after infection [14]. Symptoms that can be at
least partially attributed to pancreatitis are weight loss and stooped posture, with the latter
resulting most likely from abdominal pain. In an earlier attempt at reducing or eliminating
this health burden of the myocarditis model, we engineered a CVB3 strain that was
attenuated for the infection of the pancreas and, in so doing, we achieved reduced animal
suffering [15]. However, the pancreas-attenuated virus was less effective in provoking
myocarditis and this constrained the experimental approach.
Here, we propose an alternative strategy for improving the well-being of experimental
animals, which involves treating mice that were infected with the wild-type virus with an
analgesic drug. In accordance with the animal welfare act of the European Union (Directive
2010/63/EU), the application of analgesia for infection and other inflammatory disease
models may be considered as a suitable intervention to increase the well-being of the
animals. Nevertheless, analgesics, such as nonsteroidal anti-inflammatory drugs, and also
opioids exert immune modulating properties and these might affect the model’s defining
characteristics. Among the many drugs available for the relief of pain, we focused our
research on tramadol, which is an opioid that shows multifaceted immunomodulatory
properties [16,17]. Tramadol is a centrally acting analgesic drug that is used for the treat-
ment of intermediate to severe pain [18,19]. Its analgesic efficacy is based on a complex
interaction between the adrenergic, the opiate, and the serotonin receptor systems [20].
Tramadol is a weak opioid agonist, with specific selectivity for the µ receptor, and a weak
inhibitor of the re-uptake of norepinephrine and serotonin [21,22]. Tramadol shows no
class-specific side-effects, such as respiratory depression, constipation, or sedation [20].
Moreover, the immunomodulatory properties of this opioid can be altered by introducing
a preconditioning phase prior to the induction of pain. In contrast to biologically relevant
immunomodulation, it was noted after a short-term application of this drug in mice studies
that a prolonged treatment protocol showed no relevant immune modification, while the
analgesic effect remained [22]. As a further advantage, tramadol can be administered orally
via drinking water and further interventions, such as subcutaneous (s.c.) or intraperitoneal
(i.p.) injections, required for other opioids and the associated additional health burdens
to the existing infection are not necessary [23]. Here, we set up a study using an estab-
lished analgesic dosage of 0.1 mg/mL tramadol in the mouse model of CVB3 myocarditis
to investigate the impact of this analgesic strategy on the two main determinants of the
myocarditis model, which are the the virus-triggered cytotoxicity and the inflammatory
response.
2. Materials and Methods
2.1. Animals and Virus
Male C57BL/6J mice were purchased from Charles River, Germany and housed in
the animal facility at the Charité University Medical Center. The study was performed in
accordance with the German Animal Welfare Act, which is based on the Directive of the
European Parliament and was approved by the Committee on the Ethics of Animal Ex-
periments of Berlin state authorities—“Landesamt für Gesundheit und Soziales” (LaGeSo;
permit number G0026/20). Myocarditis was induced in male mice by a intraperitoneal
injection of 1 × 105 plaque forming units (pfu) of a cardiotropic CVB3 variant (Nancy
strain) [2]. For analgesia, Tramal® (tramadol hydrochloride solution 100 mg/mL; Grü-
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nenthal GmbH, Aachen, Germany) 0.1 mg/mL was administered via drinking water (tap
water) and was renewed daily. Tramadol treatment begun seven days before infection and
was continued until the day of analysis. The untreated control group also had their water
renewed daily. Water consumption rate with or without tramadol was estimated for each
cage by relative daily weight reduction in the drinking bottles. Soaked food and water gel
(2% SAFE® hydro; J. Rettenmaier & Söhne GmbH + Co.KG, Rosenberg, Germany) were
added to the cage beginning on the day of infection. In order to monitor the body weight
during infection, animals were weighed daily beginning on the day of infection.
A model-specific physical condition score (PCS) was used to monitor animal welfare.
The PCS includes activity, facial expression, grooming, and appearance. Two blinded
observers, using a score from one to five, evaluated each animal independently according
to the following. Activity after opening the cage: (1) remained in the nest and inactive
after removal to (5) highly active and climbing on the walls and lid of the cage. Facial
expression/grimace scale: (1) nose bulge, squeezed eyes, and ears drawn back to (5) clear,
open eyes, ears upright, and straight nose. Grooming: (1) shaggy and scruffy coat with
dirty rectum to (5) clean and shiny coat. Body posture (1) strongly bent and hunched during
walking to (5) normal stretched out body posture. The CVB3 infection model was analyzed
on days 1.5, 3, 5 and 8 after infection. On the day of analysis, after echocardiography, blood
was collected from isoflurane-anaesthetized mice and centrifuged at 10,000× g for 10 min
at room temperature. Separated serum was then collected and stored at −80 ◦C. Organs
were collected for further analysis, stored in HistoFix (1xPBS, 4% ROTI®Histofix; Carl Roth
GmbH, Karlsruhe, Germany) at 4 ◦C (for flow cytometry), or immediately frozen in liquid
nitrogen and stored at −80 ◦C.
2.2. Echocardiography
For echocardiography, mice were anesthetized with 1.5–2.0% isoflurane and kept
warm on a heated platform during the procedure. Temperature and ECG were mon-
itored continuously and cardiac function were assessed with a VisualSonic Vevo3100
High-Frequency Imaging System using a high-resolution (44 MHz) transducer. An experi-
enced technician, who was not aware of the specific treatment of each mouse, performed all
measurements. Standard imaging planes and measurements were obtained using standard
M-mode. Functional and dimensional calculations are based on the parasternal long axis
view of the left ventricle.
2.3. Quantification of Infectious CVB3
The amounts of infectious virus in different tissues were determined by standard
plaque assay on HeLa cells. Hela cells (ATCC CCL-2) were cultured in MEM (Life Tech-
nologies, Waltham, MA, USA) supplemented with 5% fetal calf serum (FCS) and 1%
penicillin/streptomycin (Life Technologies). Plaque assays were performed in duplicates
on 24-well cell culture plates, using 10-fold dilutions of homogenized organs to infect
cell monolayers for 30 min at 37 ◦C. After incubation, supernatants were carefully dis-
carded and cells were overlaid with Eagle’s-agar (MEM, 1% penicillin/streptomycin,
2.3 g/L NaHCO3, 9% fetal bovine serum (FBS), and 0.7% Difco Agar Noble (BD Bioscience,
Heidelberg, Germany). Two to three days after infection, cells were stained with MTT
(3-/4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide), incubated between two
and four hours, and plaques were subsequently counted.
2.4. Histology
Tissue samples were fixed overnight, rinsed with PBS, and embedded in paraffin. In
order to visualize immune cell infiltration and tissue necrosis, cross sections of 3–5 µm
thickness were cut and stained with hematoxylin and eosin (HE). Evaluation was carried
out by a pathologist as described elsewhere [24].
Viruses 2021, 13, 1222 4 of 15
2.5. Isolation of Immune Cells from Mouse Tissues
Immune cells were obtained from the bone marrow, spleen, and heart. For the analysis
of bone marrow cells, flushed bone marrow of one tibia and two femora for each mouse
was passed through a 70 µm cell strainer and centrifuged (10 min, 310× g). For red
blood cell lysis, cell pellet was re-suspended in 0.83% ammonium chloride (NH4Cl) in
PBS and incubated for 3 min at room temperature. Cells were recovered by centrifugation,
re-suspended in FACS buffer (1xPBS, 2% FBS, 2mM EDTA), and stored on ice until flow
cytometry was conducted. Splenocytes were prepared by passing the spleen tissue through
a 100 µm cell strainer, followed by RBC lysis as described above. In order to isolate immune
cells from heart tissue, the heart was flushed with 15 mL PBS and a part of the ventricle
(~20 mg) was stored in a wash medium (RPMI 1640, 2% FCS, 1% penicillin/streptomycin,
30 mM HEPES) at 4 ◦C until further preparation. Heart sections were minced and cells
were extracted by digestion using 1 mg/mL collagenase type 2 (Worthington Biochemical
Corporation, Lakewood, NJ, USA) and 0.15 mg/mL DNase I (Sigma-Aldrich, St. Louis,
MO, USA) in a wash medium for 30 min at 37 ◦C under continuous agitation. EDTA
was added at a concentration of 10 mM before samples were passed through a 70 µm cell
strainer. Erythrocyte lysis was performed as described.
2.6. Flow Cytometry
Panel for cardiac flow cytometry staining: Cells corresponding to 20 mg heart tissue
were incubated with Fc blocking reagent (Miltenyi, Bergisch Gladbach, Germany) at a
concentration of 1:50 for 20 min at 4 ◦C. Cells were then stained with the antibodies listed
below for 20 min at 4 ◦C while protected from light. Samples were washed with a FACS
buffer (PBS with 2% FCS and 2 mM EDTA) and PBS (centrifugation: 3 min at 300× g) before
Fixable Viability Dye eFluor 780 (eBioscience, San Diego, CA, USA) was applied according
to the manufacturer’s instructions. Samples were fixed in 2% formaldehyde/PBS for
30 min at room temperature and washed with PBS prior to the addition of 123count eBeads
(Thermo Fischer Scientific, Waltham, MA, USA) for the quantification of total cell number.
Antibodies were purchased from BD (CD8 clone 53-6.7, MHCII clone I-A[B]AF6-120.1, CD3
clone 145-2C11) and Biolegend (San Diego, CA, USA) (F4/80 clone BM8, CD11b clone
M1/70, Ly6G clone 1A8, CD11c clone N418, Ly6C clone HK1.4, B220 clone BD-R43-6B2,
CD4 clone RM4-5, and CD45.2 clone 104).
Panel for flow cytometry staining of spleen and bone marrow: Equal numbers of
cells were stained as described above using antibodies from BD (CD137 clone AH2, NK1.1
clone PK136, CD4 clone RM4-5, CD8 clone 53-6.7, CD3 clone 145-2C11, CD86 clone GL1,
and MHCII clone I-A[B]AF6-120.1) and Biolegend (B220 clone RA3-6B2, CD19 clone 6D5,
CD69 clone H1.2F3, CD62L clone MEL-14, CD44 clone IM7, CD45.2 clone 104, F4/80
clone BM8, CD11b clone M1/70, Ly6G clone 1A8, CD11c clone N418, Ly6C clone HK1.4,
B220 clone R43-6B2, CD206 clone CO68C2, CD169 clone 3D6.112, CD3 clone 145-2C11,
CD49b clone DX5, Ter119 clone Ter119, and CCR7 clone 4B12). The subsequent staining
procedure was dconducted as described above. Flow-cytometric analysis was conducted
on a BD FACSymphony flow cytometer and data were analyzed using FlowJo V10.6.2
software (Ashland, Wilmington, DE, USA) by applying the gating strategy depicted in the
Supplemental Figures S1–S3.
2.7. Quantitative Real-Time PCR
RNA was isolated using TRIzol (Ambion, Thermo Fischer Scientific) according to
the manufacturer’s instructions. DNA contamination was removed by digestion with
deoxyribonuclease I (Invitrogen, Thermo Fischer Scientific) at 37 ◦C for 15 min followed
by a deactivation step at 65 ◦C for 10 min. RNA was reverse-transcribed by MLV Reverse
Transcriptase (Promega, Madison, WI, USA) in combination with random hexamer primers
(Roche, Basel, Switzerland). TaqMan polymerase chain reaction (PCR) was performed
using primers and probes of TaqMan gene expression assays (Life Technologies, Thermo
Fischer Scientific) as well as the following combinations of primers and probes: murine
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HPRT; forward primer 5′-ATC ATT ATG CCG AGG ATT TGG AA-3′, reverse primer 5′-
TTG AGC ACA CAG AGG GCC A-3′, probe 5′-FAM-TGG ACA GGA CTG AAA GAC TTG
CTC GAG ATG-3′ TAMRA, and CVB3; forward primer 5′-CCC TGA ATG CGG CTA ATC
C-3′, reverse primer 5′-ATT GTC ACC ATA AGC AGC CA-3′, and probe 5′-FAM-TGC AGC
GGA ACC G-MGB-3′. A StepOnePlus real-time PCR system was used for quantitative
PCR (qPCR). HPRT served as an endogenous control and was used to calculate relative
expression using the ∆CT method.
2.8. Quantification of Cardiac Troponin T
Blood samples were collected, centrifuged and serum aliquots were stored at −80 ◦C
until analysis. For cardiac Troponin T quantification, a Cobas E411 automated analyzer
was used (Roche Diagnostics, Mannheim, Germany).
2.9. Statistics
Statistical analysis of the data was performed using GraphPad Prism v7.00 for Win-
dows (GraphPad Software, La Jolla, CA, USA). If not indicated otherwise, data summaries
are given as means± SEM. Unpaired t tests were used for two-group comparisons after the
outliers were identified using the ROUT method (Q = 1%). For multiple group comparison,
two-way ANOVA was performed after outliers were identified using the ROUT method
(Q = 1%). As post-hoc tests, Tukey’s multiple comparison was used to analyze virus effects
over time, while Sidak’s multiple comparison was used to analyze differences between the
two treatment groups. The significance threshold for all tests was set at the 0.05 level.
3. Results
In order to investigate whether tramadol treatment exerts any model-altering effects
on murine CVB3-induced myocarditis, we initiated tramadol treatment via drinking water
(0.1 µg/mL) one week prior to infection [22]. During the course of virus infection, the
activation of the immune system and developments of virus myocarditis were examined
as outlined in Figure 1A. The analysis of water consumption revealed similar drinking
behavior of mice and no effect of tramadol (Figure 1B). We observed a decrease in water
consumption during the first two days after CVB3 inoculation, which was reversible
afterwards. Mice receiving tramadol showed a slight increase in water consumption. As
observed for water consumption, the body weight of infected animals decreased markedly
between day 1 and day 3 after virus inoculation in both groups of mice (Figure 1C). We
observed no relevant alteration of the physical condition score during the investigational
period (Figure 1D).
As shown previously, the pancreas is a primary target organ for CVB3 after intraperi-
toneal injection, with peak virus titer at 36 h after infection (Figure 2A). In the following
days, the amount of virus subsided until no infectious particles were detected on day
8 p.i. (data not shown). Acute virus-induced pancreatitis resulted in pancreas destruction
(Figure 2B,C). We detected lower titers of the infectious virus in the peripheral organs, such
as liver (Figure 2D) and spleen (Figure 2E). Between days 5 and 8, CVB3 levels were no
longer measurable and no virus-induced pathological alterations were observed in these
organs (data not shown). Importantly, a comparison of both groups of mice revealed that
the treatment with tramadol had no impact on the early phase of the virus infection in
C57BL/6 mice, which is shown by the equal virus titer in the pancreas, liver, and spleen.
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Figure 1. Impact of tramadol on water consumption and body weight. (A) Time course of the Cox-
sackievirus B3 (CVB3)-induced acute myocarditis model as outlined in the methodology. (B) Water
consumption and (C) body weight were monitored daily for all experiments. (D) Mouse behavior
and well-being were observed every day after virus inoculation and a physical condition score was
calculated for each mouse. Data shown are means ± SEM and analyzed using two-way ANOVA
followed by Sidak’s multiple comparison test.
CVB3 efficiently activates the host immune system, starting with the type interferon
(IFN) I induction via pattern recognition receptors (PRR) and the subsequent activation
of innate as well as adaptive immune cells. In order to analyze the impact of tramadol
on the activation of the immune system, immune cell populations and their activity state
were assessed in primary (bone marrow) and secondary (spleen) lymphoid organs at
different time points after infection. During CVB3 inf ction, a slight decrease in the
number of B- nd T lymphocytes at the late stage of inf ction (days 5 a d 8) was observed,
while th number of NK cells incr ases continuously during the course of th infection
(Figur 3A). On day 5 p.i. the umber of NK cells were lower in the tramadol r ,
but a possible tramal-induced influence on NK cells was not observed compared to other
time points in the bone marrow and was completely absent in the spleen. Monocytes
and their precursors increase their proliferation capacity in response to inflammatory
stimuli, which is known as monocytosis. This effect was apparently prominent in the
bone marrow, with a 4-fold increase in Ly6C+ monocytes from day 1.5 to day 3 p.i. and
a further doubling by day 8 (Figure 3B). Thereby, the increase from day 1.5 to day 3 p.i.
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was more prominent in untreated mice. Moreover, an increasing number of dendritic
cells (DC) and neutrophils was measured during the course of infection, which indicates
active myelopoiesis as a reaction to virus-induced inflammatory processes. For dendritic
cells, tramadol seemed to interfere with this adaptation 8 days after infection, since in the
tramadol group CD11c+ bone marrow cell counts were lower in comparison to untreated
mice (Figure 3B). Nevertheless, this observation was not reflected in any effects, e.g., on
DC counts or in the spleen (Figure 4C), and occurred after the activation peak of DCs in
both the bone marrow and the spleen (Tables 1–4).
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Figure 2. Tramadol shows no effect on virus concentration in the pancreas. (A) Amount of infectious virus in the pancreas 
on day 1.5 (n = 12), 3 (n = 12), and 5 (n = 6) was determined by plaque assay. (B) Formalin‐fixed and paraffin‐embedded 
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neutrophils  was  measured  during  the  course  of  infection,  which  indicates  active 
myelopoiesis as a reaction to virus‐induced inflammatory processes. For dendritic cells, 
tramadol  seemed  to  interfere with  this  adaptation  8 days  after  infection,  since  in  the 
tramadol group CD11c+ bone marrow cell counts were lower in comparison to untreated 
mice (Figure 3B). Nevertheless, this observation was not reflected in any effects, e.g., on 
Figure 2. Tramadol shows no e fect on virus concentration in the pancreas. (A) Amount of infectious virus in the pancreas
on day 1.5 (n = 12), 3 (n = 12), and 5 (n = 6) was determined by plaque a say. (B) Formalin-fixed and para fin-embedded
pancreas tiss e sections were stained using hematoxylin and eosin and pancreas destruction was scored. (C) Representative
histological images of the pancreas are shown. Scale bar 50 µm. Amounts of infectious virus in (D) liver and (E) spleen on
day 1.5 (n = 12), 3 (n = 12), and 5 (n = 6) were determined by plaque assay. Data were summarized as means ± SEM and
analyzed by two-way ANOVA; * <0.05.
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Figure 3. Tramadol treatment shows no perturbation of immune cells in the bone marrow. Mice were sacrificed on day
1.5, 3, 5 and 8 after Coxsackievirus B3 (CVB3) infection and cells from bone marrow were isolated from one tibia and two
femurs, counted, and the number of lymphoid cells ((A) B cells, T cells, and natural killer cells) and myeloid cells ((B)
dendritic cells, macrophages, monocytes, and neutrophils) were quantified by flow cytometry (d 1.5 n = 6, d 3 n = 12/11, d 5
n = 6, and d 8 n = 6). Data were summarized as means ± SEM and analyzed by two-way ANOVA; * <0.05.
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Figure 4. Tra adol treat ent sho s no perturbation on immune cells in the spleen. Mice were sacrificed on days 1.5, 3, 5,
and 8 after Coxsackievirus B3 (CVB3) infection, sple ns were homogenized, and single cel s s e si
fi fl .
ly phoid cells (( ) B cells, T cells, and natural killer cells) and yeloid cells (( ) dendritic cells, acrophages, onocytes,
and neutrophils) were determined for each analysis day (d 1.5 n = 12, d 3 n = 1 , d 5 n = 6, and d 8 n = 6). Data were
summarized as means ± a l t - A. (D) Expres ion of cytokines in the sple n 3 days after
infection. RNA was isolated from spleen tissues for qPCR-analysis of the indicated genes. Expression data were normalized
to HPRT and calculated using the ∆CT method (n = 5). Data were summarized as means ± SEM and analyzed by t tests;
* <0.05.
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Table 1. CD44/CD69 expression on lymphoid cells in bone marrow.
CD4+ T Cells CD8+ T Cells
CD44+ CD69+ CD44+ CD69+
Tramadol + − + − + − + −
d 1.5 p.i. 92.8 ± 2 * 95.7 ± 1 * 11.5 ± 2 $ 6.7 ± 3 $ 69.9 ± 3 * 69.7 ± 4 * 51.9 ± 3 25.1 ± 10 #
d 3 p.i. 85.9 ± 2 * 91.1 ± 1 * 43 ± 3 34.8 ± 2 73.7 ± 3 * 76.7 ± 2 * 48.6 ± 5 45.3 ± 6
d 5 p.i. 87.1 ± 3 * 78.9 ± 4 * 16.3 ± 2 $ 11.5 ± 2 $ 71.9 ± 3 * 61.3 ± 2 * 22 ± 1.4 $,§ 15.7 ± 1 $
d 8 p.i. 45.6 ± 9 49.3 ± 12 15.9 ± 5 $ 15.5 ± 7 $ 40.3 ± 7 40.2 ± 10 14.4 ± 3 $,§ 10.2 ± 2 $
Tramadol-treated and untreated C57BL/6 mice were infected with Coxsackievirus B3 (CVB3). On day 1.5, 3, 5, and 8 after infection, single
cell suspensions from the bone marrow were analyzed by flow cytometry to quantify the expression of CD44 and CD69 in lymphoid
populations. Data shown are mean ± SEM and were analyzed using two-way ANOVA. * indicates significant differences compared to day
8 within the same treatment group. $ indicates significant differences compared to day 3 within the same treatment group. § indicates
significant differences compared to day 1.5 within the same treatment group. # indicates significant differences between the + tramadol and
− tramadol group.
Table 2. MHC class II/CD86 expression on myeloid cells in bone marrow.
Dendritic Cells Macrophages
MHC II+ CD86+ MHC II+ CD86+
Tramadol + − + − + − + −
d 1.5 p.i. 21.9 ± 2 $ 31.9 ± 5 31.9 ± 2 22.3 ± 3 3.9 ± 0.4 $ 3 ± 1 $ 47.9 ± 2 26 ± 6
d 3 p.i. 37.4 ± 4 40.5 ± 3 24.7 ± 3 23 ± 3 23.6 ± 5 27.3 ± 5 38.5 ± 4 38.9 ± 4
d 5 p.i. 21.2 ± 3 $ 18.4 ± 2 $ 3 ± 0.6 §,$ 4.5 ± 0.8 §,$ 5.1 ± 0.3 $ 5.8 ± 1 $ 2.2 ± 0.3 §,$ 3.6 ± 0.9 §,$
d 8 p.i. 18.1 ± 2 $ 17.6 ± 2 $ 0.2 ± 0.02 §,$ 0.1 ± 0.04 §,$ 1.8 ± 0.3 $ 1.8 ± 0.2 $ 0.2 ± 0.05 §,$ 0.1 ± 0.03 §,$
Tramadol-treated and untreated C57BL/6 mice were infected with Coxsackievirus B3 (CVB3). On day 1.5, 3, 5, and 8 after infection, single
cell suspensions from bone marrow were analyzed by flow cytometry to quantify the expression of MHC class II molecules and CD86 in
myeloid populations. Data shown are mean± SEM and were analyzed using two-way ANOVA. $ indicates significant differences compared
to day 3 within the same treatment group. § indicates significant differences compared to day 1.5 within the same treatment group.
Table 3. CD44/CD69 expression on lymphoid cells in spleen.
CD4+ T Cells CD8+ T Cells
CD44+ CD69+ CD44+ CD69+
Tramadol + − + − + − + −
d 1.5 p.i. 43.3 ± 2 48.2 ± 2 4.3 ± 0.4 6 ± 1 55.2 ± 2 57.1 ± 3 7.6 ± 0.8 15.5 ± 4
d 3 p.i. 39.2 ± 3 37.6 ± 3 § 20.8 ± 2 § 19.1 ± 2 § 49.9 ± 2 49.9 ± 1 § 18.5 ± 5 18.2 ± 5
d 5 p.i. 19.8 ± 1 §,$ 17.9 ± 0.8 §,$ 6.4 ± 0.3 $ 5.7 ± 0.6 $ 28.6 ± 1 §,$ 29.5 ± 1 §,$ 3.7 ± 0.3 3.6 ± 0.2
d 8 p.i. 23.5 ± 1 §,$ 23.6 ± 1 §,$ 12.3 ± 1 §,$ 9.2 ± 0.7 §,$ 30.2 ± 1 §,$ 30.2 ± 1 §,$ 8 ± 1 5.8 ± 0.4
Tramadol-treated and untreated C57BL/6 mice were infected with Coxsackievirus B3 (CVB3). On day 1.5, 3, 5, and 8 after infection,
single cell suspensions from spleen tissue were analyzed by flow cytometry to quantify the expression of CD44 and CD69 in lymphoid
populations. Data shown are mean ± SEM and were analyzed using two-way ANOVA. $ indicates significant differences compared to day
3 within the same treatment group. § indicates significant differences compared to day 1.5 within the same treatment group.
Table 4. MHC class II/CD86 expression on myeloid cells in spleen.
Dendritic Cells Macrophages
MHC II+ CD86+ MHC II+ CD86+
Tramadol + − + − + − + −
d 1.5 p.i. 23.4 ± 2 * 32.6 ± 3 * 23.8 ± 5 * 25.9 ± 2 * 10.4 ± 2 $ 22.6 ± 3 16.5 ± 4 $ 22.8 ± 2 $
d 3 p.i. 34.1 ± 6 * 30.4 ± 4 * 31.4 ± 6 * 29.8 ± 5 * 32.5 ± 6 34.1 ± 6 44.5 ± 9 44.3 ± 9
d 5 p.i. 29 ± 3 * 21.3 ± 2 * 17.3 ± 0.8 13.7 ± 1 18.1 ± 1 14.5 ± 1.5 $ 25.6 ± 1 23.4 ± 2
d 8 p.i. 2.9 ± 0.4 2.3 ± 0.2 1.3 ± 0.2 1.3 ± 0.2 8.2 ± 1 $ 9.9 ± 1 $ 0.5 ± 0.1$ 0.6 ± 0.2 $
Tramadol-treated and untreated C57BL/6 mice were infected with Coxsackievirus B3 (CVB3). On day 1.5, 3, 5, and 8 after infection, single
cell suspensions from spleen tissue were analyzed by flow cytometry to quantify the expression of MHC class II molecules and CD86
in myeloid populations. Data shown are mean ± SEM and were analyzed using two-way ANOVA. * indicates significant differences
compared to day 8 within the same treatment group. $ indicates significant differences compared to day 3 within the same treatment group.
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Tramadol treatment had no continuous effect on immune cell populations in these
experiments. As previously described [25], CVB3 infection resulted in spleen atrophy with
decreased lower total amounts of splenocytes (Figure 4A) in both groups. A similar tem-
porary effect was also visible for lymphocytes (Figure 4B). Compared to the mock treated
mice, animals that received tramadol showed a slight but not significant increase in the
total amount of splenocytes and lymphocytes, suggesting a possible immune-modulating
effect of tramadol. However, this was not observed for the bone marrow where the trend
was observed exemplify the opposite (Figure 3A,B). More prominent than the quantitative
differences of lymphoid cells in the spleen and bone marrow are the changes in their
activation state (Tables 1 and 3). High amounts of CD44+ and CD69+ T-lymphocytes are
present in both lymphatic organs in the early phase of infection. In particular, CD69+ CD4+
T-cells are markedly upregulated on day 3 p.i. in both the spleen and bone marrow, with a
3-fold to 5-fold increase compared to day 1.5. Similar results were observed for myeloid
cells. While the amounts of macrophages and dendritic cells in the spleen (Figure 4C)
and bone marrow (Figure 3C) display no collective trend during infection, the presence of
mature populations expressing MHCII and CD86 are significantly increased during the
early phase of infection (day 1.5 and d 3) p.i. in both organs (Tables 2 and 4). On day 8 p.i.
an increase in macrophages in tramadol treated mice was measured; this is an observation
that was not confirmed for other time points or myeloid cell populations in the spleen. In
this stage the inflammations and immune cell activations are subsided (Table 4, Figure 4D).
The increasing presence of activated immune cells during the early phase of infection,
especially on day 3 p.i., further resulted in an abundant IL-1β and TNF-α expression in
the spleen (Figure 4D), similar to that measured in the heart. In conclusion, analysis of
both lymphoid organs showed that differences in immune cell populations between both
treatment groups, quantitative as well as activation-related, were not consistent.
The most important part of this study is the examination of possible model-altering ef-
fects of tramadol with regard to the manifestation of CVB3-induced myocarditis. Therefore,
cardiac virus concentration, virus-induced cardiac tissue damage, and the virus-triggered
immune response were analyzed. In both mouse groups, plaque assay (Figure 5A left)
and quantification of viral genomes (Figure 5A right) demonstrated similar virus levels
in the myocardium on day 1.5. They further revealed enhanced virus titer after 3 days
and persisting virus presence until day 8 in both groups. Cardiac damage was examined
by the histological analysis of heart tissue (Figure 5C,D). Minor histological alterations
were observed on day 3 p.i., which increases in severity until day 8 and are characterized
by the inflammation of mononuclear cell infiltrates and tissue damage. Differences in
virus-induced myocardial tissue injury between the tramadol-treated and un-treated mice
were not observed.















Figure 5. Tramadol has no impact on Coxsackievirus B3 (CVB3)-induced myocarditis. (A) Quantification of viral load
in the heart. Mice were sacrificed on days 1.5, 3, 5, and 8 after CVB3 infection and the viral load was determined by the
quantification of infectious viral particles by plaque assay (left graph) and viral genomes using quantitative PCR (right
grap ). les ere taken on the different analy is days and cardiac tr ponin T was measured (d 1.5 n = 6,
d 3 n = 1, d 5 n = 6, and d 8 n = 16). (C,D) Infla mation and necro is in the heart. Formalin-fixed and p raffin-embe ded
heart tissue sections ere stained ith he atoxylin/eosin and myocarditis severity was semi-quantified using a scoring
system ranging from 0 to 4 (d 3 n = 12/11, d 5 n = 6, and d 8 n = 16). (D) Representative images of the heart sections for each
group and time point are shown. Scale bar 50 µm. (E) mRNA expression of the indicated genes in infected hearts. Expression
data were normalized to HPRT and calculated using ∆CT method (d 1.5 n = 6, d 3 n = 11, d 5 n = 6, and d 8 n = 10). Data
were summarized as means ± SEM and analyzed by two-way ANOVA. (F–H) Quantification of immune cell infiltration in
the heart 8 days after infection. Single cell suspensions from heart tissue were generated and (F) lymphoid and (G) myeloid
cells were quantified by flow cytometry. Values are shown as mean ± SEM (n = 10). Data were analyzed by t tests; * <0.05.
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We profiled the cardiac mRNA expression for the pro-inflammatory cytokines IL-6,
IL-1β and TNF-α, the Interferon stimulated gene 15 (ISG15) which is an effector of the type
I interferon response with antiviral properties, and IFN-γ and found peak levels on day
3 p.i. that subsided by day 8 (Figure 4E). Slightly increased cytokine expression levels in
tramadol-treated mice were observed on day 3, hinting at a minor immune modulating
activity of tramadol, but possible effects disappear as the infection progresses. In response
to pathogens, the cytokines play an important role in recruiting and activating immune cells
in the infected tissue. Since immune cell infiltration is a hallmark of the myocarditis model,
quantitative analyses of lymphoid (Figure 5G) and myeloid (Figure 5H) cells in cardiac
tissue were performed by flow cytometry on day 8 after virus infection. The amount
of CD45+ immune cells in the heart was similar in both treatment groups (Figure 5F).
Furthermore, the abundances of myeloid and lymphoid cells were equivalent in both
groups and thus an influence of tramadol treatment on cardiac immune cell infiltration was
not observed. Similar results were found for cardiac functional parameters measured by
echocardiography on days 0 and 8 p.i. (Table 5), where no differences between the groups of
mice were documented. Taken together, these results demonstrate that tramadol possesses
no model-altering impact on the CVB3-induced acute myocarditis in C57BL/6 mice.
Table 5. Analysis of cardiac performance.
− Tramadol + Tramadol
Baseline Day 8 Baseline Day 8
Heart rate (bpm) 480 ± 9.2 422 ± 20 * 457 ± 10.7 410 ± 22
Trace EF (%) 53.7 ± 1.2 52.7 ± 2.5 55.1 ± 1.3 51.1 ± 2.4
Cardiac output (mL/min) 11.2 ± 0.4 10.0 ± 1 9.9 ± 0.8 10 ± 0.8
Stroke volume (µL) 23.2 ± 0.8 22.8 ± 1.5 21.4 ± 1.6 24.3 ± 1.4
Vol d (µL) 43.4 ± 1.4 43.9 ± 1.9 39.5 ± 2.4 45.5 ± 1.7
Vol s (µL) 20.2 ± 0.9 21 ± 1.4 18.1 ± 1 21.2 ± 1.3
LVID-d (mm) 3.7 ± 0.04 3.7 ± 0.07 3.7 ± 0.06 3.8 ± 0.05
LVID-s (mm) 2.7 ± 0.06 2.8 ± 0.08 2.7 ± 0.06 2.8 ± 0.09
Tramadol-treated and untreated C57BL/6 mice were infected with CVB3. Echocardiography was performed
at baseline (day 0) and after 8 days, using a Vevo 3100. Data shown are mean values ± SEM and were
analyzed using two-way ANOVA. * indicates a significant change (p < 0.05) between day 0 and day 8 p.i.;
n = 16. EF = ejection fraction; bpm = beats per minute; Vol d/s = end-diastolic/systolic left ventricular volume;
LVID-d/s = left ventricular diameter at diastole/systole.
4. Discussion
Animal studies have contributed much to our current knowledge of etiology, progres-
sion, and molecular pathogenesis of myocarditis. They further increased our understanding
of the role of the immune system in cardiac inflammatory disease and represents an essen-
tial tool for the development and testing of causative as well as symptomatic therapies [26].
In recent years, there has been increasing consideration of the use of analgesia in animal
infection models with a severe disease burden, such as the CVB3 infection model. Although
the increasing emphasis on animal welfare is legitimate, the integrity of the animal model
has to be ensured and therefore strategies to improve animal welfare require appropri-
ate in vivo testing. Almost all analgesics, such as nonsteroidal anti-inflammatory drugs
and opioids, are thought to interact with the immune system and thus affect one of the
main model-defining hallmarks needed for the proper manifestation of CVB3-triggered
myocarditis [16,27]. Little has been conducted to study the impact of opioids on the murine
immune system and no data exist for the impact of analgesics on CVB3-myocarditis. There-
fore, we analyzed the impact of tramadol in CVB3-infected C57BL/6 mice, a mouse strain
that is often used to study acute viral myocarditis. We demonstrated that tramadol, which is
a synthetic opiate used for analgesia in humans and animals, exerts no immune modulating
impact that affects the murine CVB3-induced myocarditis model.
In our study, tramadol was given seven days prior to CVB3 infection to avoid pre-
viously described immune modifications that were detected directly after tramadol ad-
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ministration [22]. We propose such a precondition phase with tramadol treatment prior to
infection as a general concept for the CVB3 myocarditis model. The infection with CVB3
Nancy in C57BL/6 mice, as presented here, had no relevant effect on the physical condition
score and mice developed a mild disease. This ultimately resulted in the fact that the
analgesic effect by tramadol could not be scaled directly in our model. Nevertheless, we
used the dosage of 0.1 mg/mL tramadol, for which a profound analgesic effect was proven
earlier in mice after applying an osteotomy model. In this model, tramadol did not induce
well-known opioid-related side effects such as reduced drinking behavior or decreased
body weight [23]. In accordance with these data, we did not observe a drop in the water
intake of the tramadol-treated mice compared to mice receiving only water. It is known
that opioid analgesics may affect cardiac function with decreased blood pressure, heart rate,
and cardiac output. This was not observed for tramadol in humans [28] and our analysis
of cardiac function in both mice groups also revealed no effect of tramadol.
As a mode of their action, opioids interact with the immune system [27]. On the one
hand, the immune system is important during CVB3 myocarditis for viral elimination by
directly recognizing and killing infected cells [13] and possible immunosuppressive effects
by opioids could encourage infection by viruses. A worsened disease outcome resulting
from increased virus replication could be the consequence. Quantification of infectious
virus in the pancreas, heart, liver, and spleen on different days after infection revealed no
effect of tramadol on virus load or on virus clearance. As mentioned earlier, the immune
system in the virus-induced myocarditis is not only necessary for effective virus clearance,
but further induces model-defining cardiac damage by immune cell infiltration and other
inflammatory processes. In the few studies which used tramadol as an analgesic in ro-
dents, both anti-inflammatory [29] as well as pro-inflammatory [22,30] effects have been
described. Thereby Sacerdote et al. mentioned an increased proliferation of splenocytes
after acute tramadol application, but in a chronic study in which tramadol was given over
2 weeks this effect disappeared. In accordance with this observation, no differences in
the total amount of splenocytes were measured between the tramadol-treated mice and
the control group. Furthermore, as a reaction to the CVB3 infection, a similar decrease
in total splenocytes was observed in both treatment groups, which is an effect that has
previously been described [25]. A detailed analysis of the different lymphoid and myeloid
immune cell populations in the spleen and bone marrow did not reveal any significant
differences between the two groups. Moreover, the increasing maturation of antigen pre-
senting cells and subsequent activations of T cells during early virus infection were found
to be unchanged in tramadol-treated and untreated mice. Furthermore, infection-related
cytokine expression in the spleen was not altered by tramadol, as has been shown for
other opioids [31]. In experiments in rats, Bianchi M. et al. found that tramadol led to
less edema after yeast injection and less Carrageenin-induced inflammatory exudates [29].
In both models, tramadol was given a few hours before the experimental intervention.
In our study no signs of anti-inflammatory effects were found, however, indicating any
immune-modulating impact of tramadol is transient and no longer plays a role with this
chronic treatment regime. Similar to the unaffected virus-induced immune activation in the
spleen and bone marrow, no differences in cardiac immune cell infiltration were observed
on day 8 after infection. Moreover, cardiac damage and myocarditis score, which are the
most important parameters for the evaluation of myocarditis severity, remain unaffected
by tramadol.
In conclusion, our study analyzed for the first time the application of tramadol in the
murine CVB3-myocarditis model, with a particular focus on the activation of the immune
system and cardiac pathogenesis. No alterations of immune cell populations and their
activation in the spleen, bone marrow, and heart or modified cytokine expression, virus
presence, and, most importantly, heart pathology were observed when tramadol was
administered chronically seven days before infection. This shows that tramadol can be
considered as an analgesic for CVB3 infection in mice and this provides the opportunity
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to increase animal welfare without provoking disruptive effects on the key aspects of the
CVB3 myocarditis model.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/v13071222/s1, Figure S1: Gating strategy of lymphoid cells, Figure S2: Gating strategy of
myeloid cells, Figure S3: Gating strategy of heart cells.
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